RNA terminal uridylyl transferases are druggable vulnerabilities in AML but are dispensable for normal hematopoiesis.
Blocking TUT4/7 enzymes kills leukemia cells while sparing normal blood cells in mice, opening a therapeutic window rarely seen in blood cancer research.
Published in Science Advances, this study identifies TUT4/7 as therapeutically exploitable enzymes in AML using genetic deletion across human cell lines, primary patient samples, and in vivo mouse models, demonstrating both single-agent activity and venetoclax synergy. Crucially, TUT4/7 deficiency permits normal hematopoiesis and full life span in mice—a critical therapeutic window that addresses the longstanding challenge of AML-selective toxicity without myelosuppression.
What the study was
- Study design
- mechanistic_preclinical
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Sci Adv
Why it surfaced
First-in-class target identification with venetoclax combination synergy in primary patient AML samples; normal hematopoiesis sparing is key differentiator from many prior preclinical AML targets; Sci Adv publication quality; Redona Therapeutics co-authorship signals translational intent.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.